Answers are grounded in this paper and cite their sources.
Retrospective cohort study finds agranulocytosis increases 30-day mortality in patients with BSIs, indicating critical prognostic value.
Agranulocytosis and bloodstream infections (BSIs) are common complications in patients with hematological disorders and they are life-threatening. This study aims to explore the association between agranulocytosis and 30-day mortality in individuals with hematological disorders and BSIs. In this retrospective cohort study, neutrophil levels were measured in patients presenting with fever and diagnosed with a hematological disorder at Tongde Hospital of Zhejiang Province between March 2018 and August 2023. The primary outcome was all-cause 30-day mortality. Multivariate Cox proportional hazard models were used to identify factors associated with survival among patients with hematological disorders and BSIs. Survival outcomes between agranulocytosis (neutrophils < 0.5 × 10 9 /L) and non-agranulocytosis (neutrophils ≥ 0.5 × 10 9 /L) were compared via the Kaplan–Meier method. Subgroup analyses were conducted, stratified by relevant effect covariates. The study included 113 (56.8%) males and 86 (43.2%) females, with a median age of 57.4 years. The overall 30-day mortality rate was 33.7% (67/199), with mortality rate of 26.1% (24/92) in the non-agranulocytosis group and 40.2% (43/107) in the agranulocytosis group ( P = .036). After adjusting for potential confounders, a significant association between a 2% increase in the 30-day mortality rate and a 0.1 × 10 9 /L decrease in neutrophil levels was observed (95% confidence interval [CI]: 1.00–1.03, P = .006). Furthermore, agranulocytosis was associated with a 95% increase in 30-day mortality compared to non-agranulocytosis (95% CI: 1.10–3.46, P = .023). The findings from the subgroup and stratified analyses were consistent and robust. Agranulocytosis was positively associated with all-cause 30-day mortality in patients with hematological disorders and BSIs. It served as a significant early prognostic indicator for hematological patients who develop BSIs.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: